This company listing is no longer active
Resumen de acción PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 3 riesgos adicionales
Competidores de ProMIS Neurosciences, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.00 |
| 52 Week High | CA$11.10 |
| 52 Week Low | CA$3.34 |
| Beta | 1.19 |
| 1 Month Change | 14.29% |
| 3 Month Change | -34.64% |
| 1 Year Change | -17.81% |
| 3 Year Change | -50.00% |
| 5 Year Change | -71.01% |
| Change since IPO | -80.00% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| PMN | CA Biotechs | Mercado CA | |
|---|---|---|---|
| 7D | -9.4% | -3.4% | -0.1% |
| 1Y | -17.8% | -39.7% | 6.2% |
Rentabilidad vs. Industria: PMN underperformed the Canadian Biotechs industry which returned 25.2% over the past year.
Rentabilidad vs. Mercado: PMN underperformed the Canadian Market which returned 4.2% over the past year.
Volatilidad de los precios
| PMN volatility | |
|---|---|
| PMN Average Weekly Movement | 34.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Precio estable de las acciones: PMN's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: PMN's weekly volatility has increased from 18% to 34% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2004 | 7 | Gail Farfel | www.promisneurosciences.com |
Resumen de fundamentos de ProMIS Neurosciences, Inc.
| Estadísticas fundamentales de PMN | |
|---|---|
| Capitalización bursátil | CA$51.48m |
| Beneficios(TTM) | -CA$27.56m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-1.9x
Ratio precio-beneficio (PE)¿Está PMN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PMN | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$17.69m |
| Beneficio bruto | -US$17.69m |
| Otros gastos | US$3.23m |
| Beneficios | -US$20.93m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.44 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PMN a largo plazo?
Ver rendimiento histórico y comparativa